Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Bill Would Exempt Low-Risk Apps From FDA Oversight

This article was originally published in The Gray Sheet

Executive Summary

The MEDTECH Act aims to limit FDA’s regulatory oversight of software and mobile apps that carry low-risk for patients, but in a more targeted manner than previous health IT bills that have been introduced in Congress in the past year.

You may also be interested in...



Industry Gives Big Money To GOP Senators Backing Device Reforms, But Buys Into Clinton Over Trump, 14-1

In the 2016 election race, the most generous device and diagnostic industry contributors donated heavily to Senate Republicans giving legislative attention to FDA regulatory reforms – Richard Burr, N.C., Kelly Ayotte, N.H., Pat Toomey, Pa. – running close races against Democrat challengers. But while industry primarily backs GOP senators, they also favor Hillary Clinton (D) over Donald Trump (R) with their donations, 14-1.

Active Months Ahead For mHealth Regulatory Policymaking

Multiple guidances, frameworks and legislative activity on mHealth are expected to surface this fall and could have major implications on how the emerging industry is regulated.

Health IT Deregulation Bill Introduced In Senate, With Powerful Industry Backers

The PROTECT Act, which attempts to respond to some criticisms of the House SOFTWARE Act, aims to restrict FDA’s oversight of health information technology. It is backed by IBM and Verizon, among others.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel